Lexicon Pharmaceuticals LXRX Business Segments — G&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — G&A?
- Lexicon Pharmaceuticals (LXRX) reported business segments — G&A of $6.44M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — G&A changed year-over-year?
- Lexicon Pharmaceuticals's business segments — G&A decreased by 17.7% year-over-year, from $7.83M to $6.44M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — G&A?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — G&A has grown at a 5.2% compound annual growth rate (CAGR), from $21.65M to $25.23M.
- What does business segments — G&A mean?
- Operating expenses related to the management and support functions of the business segment, such as executive salaries, legal, and office overhead. These costs represent the fixed operational burden required to maintain the segment's infrastructure. Controlling these expenses is vital for improving the segment's overall operating margin.